Skip to main content

Advertisement

SpringerLink
Log in

HIV and hepatitis virus infection

  • Published:
Current Hepatitis Reports Aims and scope Submit manuscript

Abstract

As the life expectancy of patients with HIV infection increases, greater attention will need to be focused on concurrent illnesses, such as viral hepatitis, that may increase mid- to long-range morbidity and mortality. The incidence of viral hepatitis is increased in patients with HIV disease, reflecting the epidemiologic risks that these two conditions share. Coinfection with HIV seems to adversely affect the natural history of hepatitis C but may actually reduce the hepatic damage associated with hepatitis B. Immunosuppression due to HIV does not seem to significantly affect hepatitis A, E, or G. Clinicians have been reluctant to treat viral hepatitis in the HIV-infected population, but this therapeutic nihilism is unwarranted. Most studies have concluded that the treatment of hepatitis C in HIVinfected patients results in an initial efficacy and a long-term response similar to those seen in the HIV-seronegative population. Although the efficacy of interferon is reduced against hepatitis B, some nucleoside analogues are effective.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Soriano V, Garcia Samaniego J, Valencia E, et al.: Impact of chronic liver disease due to hepatitis viruses as a cause of hospital admission and death in HIV-infected drug users. Eur J Epidemiol 1999, 15:1–4. This article examines the indications for admission of HIV-infected patients to a Spanish hospital over a 4.5-year period. It highlights the need for further work to decrease the morbidity and mortality due to hepatitis viruses in this population.

    Article  PubMed  CAS  Google Scholar 

  2. Lebovics E, Dworkin BM, Heier SK, Rosenthal WS: The hepatobiliary manifestations of human immunodeficiency virus infection. Am J Gastroenterol 1988, 83:1–7.

    PubMed  CAS  Google Scholar 

  3. Hadler SC, Judson FN, O’Malley PM, et al.: Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection. J Infect Dis 1991, 163:454–459.

    PubMed  CAS  Google Scholar 

  4. Bodsworth N, Cooper D, Donovan B: The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J Infect Dis 1991, 163:1138–1140.

    PubMed  CAS  Google Scholar 

  5. Rusnak JM, Hong G: Reactivation vs. reinfection of hepatitis B in HIV seropositive individuals with previous natural immunity to hepatitis B [abstract]. In Programs and Abstracts of the XI International Conference on AIDS 1996. Vancouver; 1996:Mo.B.1239.

  6. Velasco M, Moran A, Jesus Tellez M: Resolution of chronic hepatitis B after ritonavir treatment in an HIV-infected patient. N Engl J Med 1999, 340:1765–1766.

    Article  PubMed  CAS  Google Scholar 

  7. Housset C, Pol S, Carnot F, et al.: Interactions between human immunodeficiency virus-1, hepatitis delta virus, and hepatitis B virus infections in 260 chronic carriers of hepatitis B virus. Hepatology 1992, 15:578–583.

    Article  PubMed  CAS  Google Scholar 

  8. Goldin RD, Fish DE, Hay A, et al.: Histological and immunohistochemical study of hepatitis B virus in human immunodeficiency virus infection. J Clin Pathol 1990, 43:203–205.

    Article  PubMed  CAS  Google Scholar 

  9. Mai AL, Yim C, O’Rourke K, Haethcote EJ: The interaction of human immunodeficiency virus infection and hepatitis B virus infection in infected homosexual men. J Clin Gastroenterol 1996, 22:299–304.

    Article  PubMed  CAS  Google Scholar 

  10. Colin JF, Cazals-Hatem D, Loriot MA, et al.: Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 1999, 29:1306–1310. This study examined a large group of HIV-positive and HIV-negative homosexual men with chronic hepatitis B. It confirmed the findings of previous studies showing that HBV replicates to a greater degree in the face of HIV-induced immunosuppression but, in contrast with other studies, it showed a greater incidence of cirrhosis.

    Article  PubMed  CAS  Google Scholar 

  11. Balsano C, Billet O, Bennoun M, et al.: Hepatitis B virus X gene product acts as a transactivator in vivo. J Hepatol 1994, 21:103–109.

    Article  PubMed  CAS  Google Scholar 

  12. Lee M, Lee M, Lee SK: Expression of Th1 and Th2 type cytokines responding to HBsAg and HBxAg in chronic hepatitis B patients. J Korean Med Sci 1999, 14:175–181.

    PubMed  CAS  Google Scholar 

  13. Chene G, Richard V, Morlat P, et al.: Rapid progression of HIV infection in HbeAg-positive patients. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 19:198–200.

    PubMed  CAS  Google Scholar 

  14. Scharschmidt BF, Held MJ, Hollander HH, et al.: Hepatitis B in patients with HIV infection: relationship to AIDS and patient survival. Ann Intern Med 1992, 117:837–838.

    PubMed  CAS  Google Scholar 

  15. Buti M, Esteban R, Espanol MT, et al.: Influence of human immunodeficiency virus infection on cell-mediated immunity in chronic hepatitis D. J Infect Dis 1991, 163:1351–1353.

    PubMed  CAS  Google Scholar 

  16. Buti M, Jardi R, Allende H, et al.: Chronic delta hepatitis: is the prognosis worse when associated with hepatitis C virus and human immunodeficiency virus infections? J Med Virol 1996, 49:66–69.

    Article  PubMed  CAS  Google Scholar 

  17. Milich DR, Louie RE, Chisari FV: Genetic regulation of the immune response to HBsAg T cell proliferation response and cellular interaction. J Immunol 1983, 134:1292–1294.

    Google Scholar 

  18. Odaka N, Eldred L, Cohn S, et al.: Comparative immunogenicity of plasma and recombinant hepatitis B virus vaccines in homosexual men. JAMA 1988, 260:3635–3637.

    Article  PubMed  CAS  Google Scholar 

  19. Brook MG, Karayiannis P, Thomas HC: Which patients with chronic hepatitis B virus infection will respond to alpha interferon therapy? A statistical analysis of predictive factors. Hepatology 1989, 10:761–763.

    Article  PubMed  CAS  Google Scholar 

  20. Davis GL: Interferon treatment of viral hepatitis in immunocompromised patients. Semin Liver Dis 1989, 9:267–272.

    Article  PubMed  CAS  Google Scholar 

  21. Wong DK, Yim C, Naylor CD, et al.: Interferon alpha treatment of chronic hepatitis B: randomized trial in a predominantly homosexual male population. Gastroenterology 1995, 108:165–171.

    Article  PubMed  CAS  Google Scholar 

  22. Puoti M, Rossi S, Forleo MA, et al.: Treatment of chronic hepatitis D with interferon alpha-2b in patients with human immunodeficiency virus infection. J Hepatol 1998, 29:45–52.

    Article  PubMed  CAS  Google Scholar 

  23. Marcellin P, Boyer N, Colin JF, et al.: Recombinant alpha interferon for chronic hepatitis B in anti-HIV positive patients receiving zidovudine. Gut 1993, 34(suppl):S106.

    Article  PubMed  CAS  Google Scholar 

  24. Benhamou Y, Katlama C, Lunel F, et al.: Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Ann Intern Med 1996, 125:705–712.

    PubMed  CAS  Google Scholar 

  25. Xiong X, Flores C, Yang H, et al.: Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 1998, 28:1669–1673.

    Article  PubMed  CAS  Google Scholar 

  26. Benhamou Y, Bochet M, Thibault V, et al.: Safety and efficacy of long-term adefovir dipivoxil (ADV)for lamivudineresistant (Lam-R) HBV in HIV infected patients [abstract]. Paper presented at the XIV International AIDS Conference. Barcelona, Spain, 2002 (abstract ThPeC7528).

  27. Dieterich DT, Park J, Braun J, et al.: Hepatits B virus virologic response to tenofovir disoproxil fumarate for HIV/HBV coinfected patients resistant to lamivudine therapy [abstract]. Paper presented at the XIV International AIDS Conference. Barcelona, Spain, 2002 (abstract B10533).

  28. Tubiana R, Benhamou Y, Bochet M, et al.: Tenofovir disoproxil fumarate suppresses lamivudine-resistant HBV replication in patients co-infected with HIV/HBV [abstract]. Paper presented at the XIV International AIDS Conference. Barcelona, Spain, 2002 (abstract ThPeC7527).

  29. Cooper D, Cheng A, Coakley DF, et al.: Anti-hepatitis B virus activity of tenofovir disoproxil fumarate in lamivudine (LAM) experienced HIV/HBV co-infected patients [abstract]. Paper presented at the XIV International AIDS Conference. Barcelona, Spain, 2002 (abstract WePeB6015).

  30. Zylberberg H, Pol S: Reciprocal interaction between human immunodeficiency virus and hepatitis C virus infections. Clin Infect Dis 1996, 23:1117–1125.

    PubMed  CAS  Google Scholar 

  31. Wyld R, Robertson JR, Brettle RP, et al.: Absence of hepatitis C virus transmission but frequent transmission of HIV-1 from sexual contact with doubly infected individuals. J Infect 1997, 35:163–166.

    Article  PubMed  CAS  Google Scholar 

  32. Eyster ME, Alter HJ, Aledort LM, et al.: Heterosexual cotransmission of hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Ann Intern Med 1991, 115:764–768.

    PubMed  CAS  Google Scholar 

  33. Thomas DL, Villano SA: Perinatal transmission of hepatitis C virus from human immunodeficiency virus type 1. J Infect Dis 1998, 177:1480–1488.

    Article  PubMed  CAS  Google Scholar 

  34. Pappalardo BL: Effect of maternal co-infection on vertical transmission of hepatitis C virus (HCV): a meta-analysis (abstract). Paper presented at the XIV International AIDS Conference. Barcelona, Spain, 2002 (abstract ThPeC7503).

  35. Laskus T, Radkowski M, Wang LF, et al.: Hepatitis C virus quasispecies in patients infected with HIV-1: correlation with extrahepatic viral replication. Virology 1998, 248:164–171.

    Article  PubMed  CAS  Google Scholar 

  36. Cribier B, Rey D: High hepatitis viremia and impaired antibody response in patients co-infected with HIV. AIDS 1995, 9:113–116.

    Article  Google Scholar 

  37. Thomas DL, Shih JW, Alter HJ, et al.: Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users. J Infect Dis 1996, 174:690–695.

    PubMed  CAS  Google Scholar 

  38. Eyster ME, Diamondstone LS, Lien JM, et al.: Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr Hum Retrovirol 1993, 6:602–610.

    CAS  Google Scholar 

  39. Eyster ME, Fried MW, Di Bisceglie AM, Goedert JJ: Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study. Blood 1994, 84:1020–1023.

    PubMed  CAS  Google Scholar 

  40. Bierhoff E, Fischer HP, Willsch E, et al.: Liver histopathology in patients with concurrent chronic hepatitis C and HIV infection. Virchows Arch 1997, 430:271–277.

    Article  PubMed  CAS  Google Scholar 

  41. Garcia-Samaniego J, Soriano V, Castilla J, et al.: Influence of hepatitis C virus genotypes and HIV infection on histological severity of chronic hepatitis C. The Hepatitis/HIV Spanish Study Group. Am J Gastroenterol 1997, 92:1130–1134.

    PubMed  CAS  Google Scholar 

  42. Martin P, Di Bisceglie AM, Kassianides C, et al.: Rapidly progressive non-A, non-B hepatitis in patients with human immunodeficiency virus infection. Gastroenterology 1989, 97:1559–1561.

    PubMed  CAS  Google Scholar 

  43. Makris M, Preston FE, Rosendaal FR, et al.: The natural history of chronic hepatitis C in haemophiliacs. Br J Haematol 1996, 94:746–752.

    Article  PubMed  CAS  Google Scholar 

  44. Telfer P, Sabin C, Devereux H, et al.: The progression of HCVassociated liver disease in a cohort of haemophilic patients. Br J Haematol 1994, 87:555–561.

    Article  PubMed  CAS  Google Scholar 

  45. Sanchez-Quijano A, Andreu J, Gavilan F, et al.: Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C. Eur J Clin Microbiol Infect Dis 1995, 14:949–953.

    Article  PubMed  CAS  Google Scholar 

  46. Goedert JJ, Hatzakis A, Sherman KE, et al.: Lack of association of hepatitis C viral load and genotype with risk of end-stage liver disease in patients with human immunodeficiency virus coinfection. J Infect Dis 2001, 184:1202–1205.

    Article  PubMed  CAS  Google Scholar 

  47. Shimizu YK, Purcell RH, Yoshikura H: Correlation between the infectivity of hepatitis C virus in vivo and its infectivity in vitro. Proc Natl Acad Sci U S A 1993, 90:6037–6041.

    Article  PubMed  CAS  Google Scholar 

  48. Greub G, Ledergerber B, Battegay M, et al.: Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000, 356:1800–1805.

    Article  PubMed  CAS  Google Scholar 

  49. Soriano V, Kirk O, Antunes F, et al.: HIV-1 progression in hepatitis C-infected drug users. Lancet 2001, 357:1361–1362.

    Article  PubMed  CAS  Google Scholar 

  50. Sulkowski MS, Moore RD, Mehta SH, et al.: Hepatitis C and progression of HIV disease. JAMA 2002, 288:199–206.

    Article  PubMed  Google Scholar 

  51. Rancinan C, Neau D, Saves M, et al.: Is hepatitis C virus co-infection associated with survival in HIV-infected patients treated by combination antiretroviral therapy? AIDS 2002, 16:1357–1362.

    Article  PubMed  Google Scholar 

  52. Justice AC, Wagner JH, Fusco GP, et al.: HIV survival: liver function tests independently predict survival [abstract]. Paper presented at the XIV International AIDS Conference. Barcelona, Spain, 2002 (abstract MoOrB1058).

  53. Piroth L, Duong M, Quantin C, et al.: Does hepatitis C virus co-infection accelerate clinical and immunological evolution of HIV-infected patients? AIDS 1998, 12:381–388.

    Article  PubMed  CAS  Google Scholar 

  54. Woitas RP, Ahlenstiel G, Iwan A, et al.: Frequency of the HIV-protective CC chemokine receptor 5-_32/_32 genotype is increased in hepatitis C. Gastroenterology 2002, 122:1721–1728.

    Article  PubMed  CAS  Google Scholar 

  55. Madhava V, Feldman J, Philpott S, et al.: Association of CCR5-D32 mutation with hepatitis C seroprevalence and incidence in a large cohort of women [abstract]. Paper presented at the XIV International AIDS Conference. Barcelona, Spain, 2002 (abstract TuPeA4365).

  56. Gavazzi G, Richallet G, Morand P, et al.: Effects of double and triple antiretroviral agents on the HCV viral load in patients co-infected with HIV and HCV. Pathol Biol 1998, 46:412–415.

    PubMed  CAS  Google Scholar 

  57. Rutschmann OT, Negro F, Hirschel B, et al.: Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients co-infected with HIV. J Infect Dis 1998, 177:783–785.

    Article  PubMed  CAS  Google Scholar 

  58. Benhamou Y, Di Martino V, Bochet M, et al.: Factors affecting liver fibrosis in HIV and hepatitis C coinfected patients: impact of protease inhibitor therapy. Hepatology 2001, 34:283–287.

    Article  PubMed  CAS  Google Scholar 

  59. Nunez M, Rios P, Martin-Carbonero, et al.: Role of hepatitis C virus genotype in the development of severe transaminase elevation after the introduction of antiretroviral therapy. J Acquir Immune Defic Syndr Hum Retrovirol 2002, 30:65–68.

    Google Scholar 

  60. Wit FW, Weverling GJ, Weel J, et al.: Incidence of and risk factors for severe hepatotoxicity associated with antretroviral combination therapy. J Infect Dis 2002, 186:23–31.

    Article  PubMed  CAS  Google Scholar 

  61. Sulkowski MS, Thomas DL, Mehta SH, et al.: Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002, 35:182–189.

    Article  PubMed  CAS  Google Scholar 

  62. Manns MP, McHutchinson JG, Gordon SC, et al.: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001, 358:958–965. This paper did not examine an HIV-infected population, but it was a vital factor in the movement away from non-peg-IFN.

    Article  PubMed  CAS  Google Scholar 

  63. Soriano V, Sulkowski M, Bergin C, et al.: Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV international panel. AIDS 2002, 16:813–828. The leaders in the field collaborated for this update on all aspects of HIV-HCV coinfection.

    Article  PubMed  Google Scholar 

  64. Sulkowski MS, Felizarta F, Slim J, et al.: Multi-center, randomized open-label study of the safety and efficacy of interferon (IFN) alfa-2b plus ribavirin (RBV) for the treatment of hepatitis C virus (HCV) in HIV-infected persons [abstract]. Paper presented at the XIV International AIDS Conference. Barcelona, Spain, 2002 (abstract ThPeC7496).

  65. Chung R, Andersen J, Alston B, et al.: A randomized, controlled trial of pegylated interferon-alfa-2a plus ribavirin vs interferon-alfa-2a plus ribavirin for the treatment of HCV in HIV coinfection: ACTG A5701 [abstract]. Paper presented at the 9th CROI. Seattle, WA, 2002 (abstract 2315).

  66. Rockstroh JK, Sculz C, Mauss S, et al.: Pegylated interferon-alpha and ribavirin therapy for hepatitis C in HIV-coinfected patients: 24 weeks results [abstract]. Paper presented at the XIV International AIDS Conference. Barcelona, Spain, 2002 (abstract WePeB6025).

  67. Khalili M, Hoffman-Terry M, Hassanein T, et al.: Safety and efficacy of peginterferon alpha-2a (40kd) (Pegasys) in the treatment of patients coinfected with HIV and HCV: preliminary results from a randomized, multicenter trial [abstract]. Paper presented at the 52nd AASLD. Dallas, TX, 2002 (abstract 623).

  68. Nieto L, Angel J, Gazzard B, et al.: Antiviral activity and tolerability of peg-intron in HIV patients failing HAART [abstract]. Paper presented at the 1st IAS Conference on HIV pathogenesis and treatment. Buenos Aires, South America, 2001 (abstract 115).

  69. Weisz K, Kreiswirth S, McMeeking M, et al.: Erthyropoetin use for ribavirin/interferon induced anemia in patients with hepatitis C [abstract]. In Proceedings of the Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, 1998:325.

  70. Gerard Y, Maulin L, Yazdanpanah Y, et al.: Symptomatic hyperlactatemia: an emerging complication of antiretroviral therapy. AIDS 2000, 14:2723–2730.

    Article  PubMed  CAS  Google Scholar 

  71. Smith DM, Puoti M, Sulkowski M, et al.: Symptomatic hyperlactatemia during a large hepatitis C treatment trial in HIV/ HCV co-infected participants on stable antiretroviral therapy [abstract]. Paper presented at the XIV International AIDS Conference. Barcelona, Spain, 2002 (abstract MoOrB1059).

  72. Schlaak JF, Schramm C, Radecke K, et al.: Brief Report: sustained suppression of HCV replication and inflammatory activity after interleukin-2 therapy in patients with HIV/ hepatitis C virus coinfection. J Acquir Immune Defic Syndr Hum Retrovirol 2002, 29:145–148.

    CAS  Google Scholar 

  73. Vento S, Garafano T, Renzini C, et al.: Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998, 338:286–290.

    Article  PubMed  CAS  Google Scholar 

  74. Neilsen GA, Bodsworth NJ, Watts N: Response to hepatitis A vaccination in human immunodeficiency virus-infected and -uninfected homosexual men. J Infect Dis 1997, 176:1064–1067.

    Article  PubMed  CAS  Google Scholar 

  75. Balayan MS, Fedorova OE, Mikhailov MI, et al.: Antibody to hepatitis E virus in HIV-infected individuals and AIDS patients. J Viral Hepatol 1997, 4:279–283.

    Article  CAS  Google Scholar 

  76. Rey D, Fraize S, Vidinic J, et al.: High prevalence of GB virus C/ hepatitis G virus RNA in patients infected with human immunodeficiency virus. J Med Virol 1999, 57:75–79.

    Article  PubMed  CAS  Google Scholar 

  77. Woolley I, Valdez H, Walker C, et al.: Hepatitis G virus RNA is common in AIDS patients’ plasma but is not associated with abnormal liver function tests or other clinical syndromes. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 19:408–412.

    PubMed  CAS  Google Scholar 

  78. Xiang J, Wunschmann S, Diekema DJ, et al.: Effect of coinfection with GB virus C on survival among patients with HIV infection. N Engl J Med 2001, 345:707–714.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mount Sinai Medical Center, 1 Gustave Levy Place, Box 1118, 10029-6574, New York, NY, USA

    Winston Lee MD, Michael A. Poles MD & Douglas T. Dieterich MD

Authors
  1. Winston Lee MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael A. Poles MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Douglas T. Dieterich MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lee, W., Poles, M.A. & Dieterich, D.T. HIV and hepatitis virus infection. Current Hepatitis Reports 1, 30–37 (2002). https://doi.org/10.1007/s11901-002-0006-6

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11901-002-0006-6

Keywords

Search

Navigation